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Abstract
Introduction: Adult-onset still’s disease (AOSD) is a rare systemic inflammatory disorder in which abnormalities in
inflammatory cytokines production appear to play a pathophysiological role. Our previous work has reported
increased expression of macrophage migration inhibitory factor (MIF) and revealed its correlation with disease
severity and activity in AOSD. A -173 G/C single nucleotide polymorphism (SNP) (rs755622) and a -794 CATT5-8
repeat (rs5844572) in the MIF promoter have been reported. In this study, we sought to explore the relationship
between functional MIF promoter polymorphisms and MIF expression in AOSD.
Methods: 100 patients and 200 controls were recruited in the study. A polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) assay was utilized to analyze the -173 G/C SNP (rs755622) and PCR-based size
discrimination assay was applied to detect the -794 CATT5-8 repeat (rs5844572) in the MIF promoter. Plasma MIF levels
were measured by ELISA. MIF mRNA levels were quantified by real-time reverse transcription (RT)-PCR. Bisulfate
genomic sequencing was employed to evaluate DNA methylation status within the MIF promoter.
Results: We identified that the frequencies of MIF -794 CATT5 (P = 0.001) allele and the expression of MIF (P <
0.001) were increased in patients compared to healthy controls. Plasma levels of MIF in patients with CC genotype
were higher than those of patients with GC or GG genotypes (P = 0.05). In patients with established AOSD, a
higher frequency of -794 CATT7 containing MIF genotypes was observed in those with liver dysfunction (P = 0.009).
Haplotype analysis revealed a higher representation of the MIF haplotype defined by -173*C/-794 CATT5 (C5) in
AOSD patients (P = 0.001).
Conclusion: Functional promoter polymorphisms in the MIF gene influence plasma MIF levels in AOSD and may
contribute to disease susceptibility or clinical presentation of AOSD.
Keywords: macrophage migration inhibitory factor, adult onset still’s disease, gene polymorphism, gene expres-
sion, DNA methylation
Introduction
Adult-onset still’s disease (AOSD) is a rare systemic
inflammatory disorder characterized by spiking fevers, an
evanescent salmon pink rash, arthritis, leucocytosis, and
multiple organ involvement [1]. Although nosologically
recognized for over one century, the etiology of this disease
remains unknown. In a Canadian study, genetic evaluation
revealed an association between HLA (human leukocyte
antigen). B17, B18, B35, DR2 and AOSD [2]. Potential
genetic risks for AOSD outside of the polymorphic HLA
locus have also been explored. Sugiura and colleagues have
reported that a promoter haplotype of the IL-18 gene was
associated with AOSD in a Japanese population [3]. There
is also evidence that monocyte/macrophage-derived
inflammatory cytokines such as IL-1, IL-6, and TNF-a may
play a physiological role in AOSD [4], which have been
successfully therapeutically targeted in certain diseases
[5,6].
Macrophage migration inhibitory factor (MIF) is a pleio-
tropic cytokine involved in the regulation of innate and
adaptive immunity [7]. Its main actions are to counter-
regulate the immunosuppressive and anti-inflammatory
actions of glucocorticoids [8,9] and to inhibit the activa-
tion-induced apoptosis of macrophages [10]. The genetic
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deletion of MIF in animal models leads to a global
decrease in the production of monocyte/macrophage-
derived mediators such as IL-1b, IL-12, and TNF-a,
confirming MIF’s role as an upstream regulator of the
inflammatory cascade [11], Evidence of a role for MIF dur-
ing inflammation has been established in several autoim-
mune inflammatory diseases. Our previous work has
revealed an association of serum MIF expression with dis-
ease activity and severity in AOSD [12], which was later
confirmed by Becker and colleagues [13].
The molecular mechanisms regulating the expression of
the MIF gene (MIF) [Genebank GeneID:307284] are still
largely unknown. In recent years, genetic studies have
established that functionally distinct alleles influence dis-
ease susceptibility and severity, and have supported pro-
spects for pharmacological development. Functional
polymorphisms in the MIF gene promoter have been stu-
died in autoimmune diseases such as juvenile inflamma-
tory arthritis [14], rheumatic arthritis [15], scleroderma
[16], and systemic lupus erythematosus (SLE) [17]. A G/C
single nucleotide polymorphism (SNP) at position -173
(rs755622) [18] and a CATT tetranucleotide repeat at
position -794(rs5844572) have been described and are
associated with altered transcriptional activity of the MIF
promoter. Based on these considerations, we sought to
investigate a possible genetic link between MIF promoter
polymorphisms and MIF expression in AOSD.
DNA methylation plays an important role in the epige-
netic regulation of gene expression. Cytosine residues
methylated by DNA methytransferases within CpG sites
can inhibit gene transcription by interfering with the bind-
ing of the regulatory factors to DNA. A CpG island con-
sisting of 34 CpG sites was detected in the MIF gene
promoter (ranging from -300 base pairs to +1 base pair)
and we further explored whether the methylation status of
the MIF gene promoter affected MIF gene expression in
AOSD.
Materials and methods
Recruitment of study subjects
A total of 100 patients (30 men and 70 women) who ful-
filled the Yamaguchi criteria for AOSD were recruited
into this study [19]. These patients were ethnic Han
Chinese. Routine blood tests including erythrocyte sedi-
mentation rate (ESR), serum ferritin, liver enzymes,
rheumatoid factor (RF), antinuclear antibody (ANA), and
anti-double-stranded DNA antibody were tested. Micro-
biology investigation, including bacterial and viral testing,
imaging tests, and bone marrow and lymph node biopsies
were performed when clinically indicated. Patients with
infections, malignancies and other autoimmune diseases
were excluded. Healthy volunteers biologically unrelated
to patients were recruited as controls. Genomic DNA was
extracted from all blood samples. All patients and controls
were informed about the purpose of our study and con-
sented to participate in the study. This study was approved
by the institutional review board of Shanghai Jiaotong
University.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) genotyping for the
MIF -173 G/C SNP
A 366-bp DNA fragment was produced by PCR with the
forward primer 5’-ACT-AAG-AAA-GAC-CCG-AGG-C-
3’and reverse primer 5’-GGG-GCA-CGT-TGG-TGT-
TTA-C-3’. Amplification of 150ng of genomic DNA was
performed in a 25-μL reaction volume containing 1.25
units of Taq DNA Polymerase, 1 μL of forward and
reverse primer, 12.5 μL of 2× buffer and deoxynucleotide
triphosphate (dNTP). The amplification consisted of an
initial holding at 94°C for 3 minutes, followed by a three-
step PCR program: 94°C for 30 seconds, 55°C for 30 sec-
onds, and 72°C for 1 minute for 40 cycles. A final cycle of
72°C for 5 minutes completed the reaction. A 10-μL final
reaction consisted of amplified PCR product (6 μL), 10×
buffer (2 μL), FastDigest AIUΙ (1 μL) and distilled water
(1 μL) was conducted at 37°C for 3 hours. The digested
products were resolved on a 3% agarose gel and visualized
using UV transillumination.
Genotyping for the MIF -794 CATT5-8 repeat
polymorphism
Genomic DNA (150 ng) was subjected to PCR for one
cycle at 94°C for 3 minutes, 40 cycles at 94°C for 30 sec-
onds, 55°C for 30 seconds and 72°C for 1 minute, followed
by 72°C for 5 minutes. The forward primer was 5’-TTG-
CAC-CTA-TCA-GAG-ACC-3’ and was labeled with a
FAM fluorescent dye, the reverse primer was 5’-TCC-
ACT-AAT-GGT-AAA-CTC-G-3’. The 25 μL PCR reac-
tion volume contained 150 ng of genomic DNA, 1.25
units of Taq DNA Polymerase, 1 μL of forward and
reverse primer, 12.5 μL of 2× buffer and dNTP. The
amplification included an initial holding at 94°C for 3 min-
utes, followed by a three-step PCR program: 94°C for
30 seconds, 55°C for 30 seconds and 72°C 1 minute for
40 cycles, and finally, 72°C for 5 minutes. The PCR pro-
duct was appropriately diluted and supplemented with
GeneScan 500 size standard (Applied Biosystems, Foster
City, CA, USA) The mixture was then separated on a
50-cm polyacrylamide gel at 15000 V for 45 minutes on
an ABI 3730XL capillary sequencer and analyzed with
GeneMapper 4.0 software (Applied Biosystems). The four
PCR product sizes were 207 bp, 211 bp, 215 bp,219 bp in
length and these corresponded to 5-, 6-, 7-, and 8-CATT
repeats respectively. To address the issue of multiple testing,
we used the permutation test in R[20]. The permutation test
was used in those instances in which the comparisons pro-
duced marginal P-values.
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MIF ELISA
Plasma MIF levels were measured using the quantikine
human MIF kit (R&D systems, Minneapolis MN, USA).
According to the suggested protocol, 100 μL of assay
diluent and 50 μL of diluted standard or samples were
added to a microplate precoated with capture antibody.
After incubation for 2 hours at room temperature and
four washes, 200 μL of MIF conjugate was added to
each well for another 2 hours on the shaker. Color was
developed by incubating with substrate solution for
30 minutes at room temperature. Stop solution was
used to terminate the reaction and absorbance was read
by a microplate reader set to 450 nm.
Isolation of peripheral blood mononuclear cells and RNA
preparation
Peripheral blood mononuclear cells (PBMC) were isolated
from anticoagulated blood using Ficoll-HyPaque gradient
centrifugation (Sigma-Aldrich, St Louis, Mo, USA), which
was performed at 400 g for 30 minutes at 25°C. The
PBMC-enriched interphase was collected and washed with
PBS. Total RNA was extracted from PBMC using Trizol
Reagent (Invitrogen, Carlsbad, CA, USA). The quality and
quantity of total RNA were measured using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Then RNA was puried using
DNase as follows: 20 ìg of total RNA, 5 ìL of 10×DNase I
buffer, 20 U of RNase inhibitor, 10 U of DNase I. The
RNA then was quantified and up to 400 ng RNA was
reverse-transcribed into cDNA in a final volume of 10 ìL
using the Reverse Transcription Kit (Takara Bio Inc, Otsu,
Japan).
Real-time PCR
Expression levels of the MIF gene were quantified by
real-time PCR with the SYBR Green PCR Master Mix
(Takara). PCR reactions were carried out in triplicate
with the 7900 Real-time PCR System (Applied Biosys-
tems). The sequence of the primers used for PCR were
as follows: forward primer: 5’-GAACCGCTCCTACAG-
CAAGCT-3’; reverse primer:
5’-GCGAAGGTGGAGTTGTTCCA-3’. The thermal
cycling conditions included 10 minutes at 95°C and
then 40 cycles of amplification for 3 seconds at 95°C
and 20 seconds at 60°C. A melting curve analysis was
performed after amplification. The efficiency of real-
time PCR is 99.4%. The quantity of mRNA was calcu-
lated by normalizing the cycle threshold (CT) value of
MIF to the CT of the housekeeping gene, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), in the same
sample according to the following formula: the average
GAPDH CT was subtracted from the average MIF CT;
the result represents the ΔCT. This ΔCT is specific and
can be compared with the ΔCT of a calibration sample.
The subtraction of control ΔCT from the ΔCT of the-
case group is referred to as ΔΔCT. The relative quantifi-
cation of expression of MIF was determined by using
2-ΔΔCT.
Bisulfite methylation assay
Genomic DNA was extracted from PBMCs (Qiagen,
Hilden, Germany) and 500 ng was bisulfite-modified
using the EZ DNA methylation gold kit according to
the manufacturer’s instruction (Zymo research, Orange,
CA, USA). We performed PCR of 250 ng of bisulfite-
modified DNA for one cycle at 94°C for 3 minutes, 40
cycles at 94°C for 30 seconds, 55°C for 30 seconds and
72°C 1 minute, followed by 72°C for 5 minutes. The
HotStart Taq DNA Polymerase system (Takara) was
used: forward primer: 5’- TGTGGTTTAAAGATAG-
GAGGTATAGG -3’; reverse primer: 5’- TAATAA-
CAAAAAAACCAAAAAACCC-3’. The PCR product
was purified with a gel extraction kit and then cloned
into the pGM-T vector. The positive cloning was
selected for sequencing to confirm the methylation sta-
tus of each CpG site within the MIF promoter (ranging
from -300 base pairs to +1 base pair).
Statistical analysis
The -173 G/C SNP and -794 CATT5-8 repeat genotype and
allele frequencies in patients and controls were compared
using Pearson’s chi-square test and when appropriate,
Fisher’s exact test. No deviation from Hardy-Weinberg
equilibrium was seen. The plasma MIF expression was
presented as median ± SD. The non-parametric Mann-
Whitney U-test was conducted to compare MIF expression
between case-control groups or subset groups. All calcula-
tions were performed using SPSS version 13.0 analysis soft-
ware. A permutation test was used. Given the multiple
groups, the Bonferroni correction was applied and P <
0.0167 was considered significant for the -173G/C data and
P <0.0045 was considered significant for the -794CATT
repeat data.
Results
Comparison of demographic and clinical characteristics
of AOSD patients
The demographic and clinical characteristics of our
recruited AOSD patients are shown in Table 1. There
was a lower incidence of hydrohymenitis in our study
group compared to other countries or ethnic populations.
No apparent differences were found in the proportion of
other clinical manifestations [21-24] (Table 1).
MIF -173 G/C SNP analysis
No deviation from Hardy-Weinberg equilibrium was
observed in genotype frequencies for the polymorph-
isms. The -173G/C SNP genotype and allele
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frequencies in AOSD patients and healthy controls are
shown in Table 2. The CC genotype frequency was not
significantly higher in patients than in controls (5% ver-
sus 0.5%, P = 0.017). There were no differences in the
frequencies of the other two genotypes (GC P = 0.33;
GG P = 0.072), and there was no difference in -173*C
allele frequency between patients and controls (31% ver-
sus 21.5%, P = 0.072).
MIF -794 CATT5-8 repeat analysis
The -794 CATT repeat genotype and allele frequencies
are shown in Table 3. The -794 CATT5-containing gen-
otypes were significantly higher in the AOSD group
compared with controls (49.5% versus 35.1%, P = 0.001)
which suggests that the carriage of the -794 CATT5
allele may contribute to the development of AOSD.
After permutation testing this difference remained sig-
nificant (P = 0.018). There was no difference in the fre-
quency of the high expression -794 CATT7-containing
genotype in the comparison of AOSD patients with con-
trols (17.4% versus 16.8%, P = 0.854). After permutation
testing, the P-value was 0.911 in patients compared with
controls.
MIF polymorphisms and AOSD clinical manifestations
AOSD patients were stratified according to clinical mani-
festations. The frequencies of the -174 G/C SNP and the
-794 CATT5-8 genotypes were compared among patients
with or without clinical features (myalgia, lymphadenopa-
thy, liver damage, hydrohymenitis). Patients with liver
damage, defined as elevated hepatic transaminases, had a
higher frequency of the high-expression -794 CATT7 gen-
otype compared with those without this manifestation
(55.2% versus 30.8%, P = 0.009). No statistical differences
were detected in other genotypes.
Haplotype frequency analyses
The reconstructed frequencies of each possible haplotype
based on the observed genotype data are shown in Table 4.
The relative percentage of each haplotype was compared in
AOSD patients and controls. The -173G/C and -794
CATT5-8 polymorphisms were in linkage disequilibrium.
The AOSD patients had a significantly higher frequency of
the haplotype defined by -173*C allele and -794 5-CATT
repeats (C5) compared with controls (P = 0.001, odds ratio
(OR) 5.534, 95% CI 1.712, 17.882) and the P-value on per-
mutation testing was 0.021. The frequency of the G5 hap-
lotype in AOSD patients also was higher than that in
controls (P = 0.032, OR 1.474, 95% CI 1.034, 2.101).
Table 1 Clinical manifestations of patients enrolled in the study








Male/female 3/7 3/4 10/7 2/3 9/11
Age, years, range 15, 70 16, 35 7, 44 16, 65 17, 57
Positive patients, %
Fever(temperature ≥39°C) 99 83 100 84 100
Rash 88 90 84 82 80
Arthritis 98 98 100 98 100
Lymphadenopthy 47 45 48 36 50
Hepatoasplenomegaly 41 48 72 71 40
Hydrohymenitis 32 57 48 53 *
*Data incomplete.
Table 2 Genotype and allele frequencies for -173 SNP






C/C 5(5%) 1(0.5%) 0.017
G/C 26(26%) 42(21%) 0.33
G/G 69(69%) 157(78.5%) 0.072
Allele
-173*C 36(18%) 44(11%) 0.017
MIF, macrophage migration inhibitory factor; SNP, single nucleotide
polymorphism.
Table 3 Genotype and allele frequencies for -794 CATT
repeat polymorphism
MIF -794 STR Patients (n = 95) Controls
(n = 188)
P-value
5/5 22(23.16%) 21 (11.17%) 0.008
5/6 34(35.79%) 75 (39.89) 0.503
5/7 15(15.79%) 14 (7.45%) 0.029
5/8 1(1.05%) 1 (0.53%) 0.621
6/6 9(9.47%) 34 (18.09%) 0.057
6/7 10(10.53%) 23 (12.23%) 0.673
6/8 0( 0%) 4 (2.13%) 0.152
7/7 4 (4.21%) 10 (5.32%) 0.685
7/8 0 (0%) 6 (3.19%) 0.078
Allele frequencies
-794 CATT5 94(49.5%) 132(35.1%) 0.001
-794 CATT7 33(17.4%) 63(16.8) 0.854
MIF, macrophage migration inhibitory factor.
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However, the P-value was 0.93 after permutation testing.
There was a significant reduction in the -173*G/-794 6-
CATT(G6) haplotype in AOSD patients (P = 0.007, OR
0.596, 95% CI 0.408, 0.871) and the P-value on permuta-
tion testing was 0.046.
Plasma levels of MIF
A difference in circulating plasma MIF levels was noted
between AOSD patients and controls. The concentration
of MIF was 83.28 ± 112.80 ng/mL in patients while
49.39 ± 29.27 ng/ml in controls (P < 0.001, Figure 1A).
Median concentrations of MIF were 110.7 ng/mL in the
CC group and 76.43 ng/mL in the GC+GG group of
patients (P = 0.05, Figure 1A). There was no difference
between two groups stratified by the -794 CATT5-
containing genotype or the -794 CATT7-containing gen-
otype (not shown).
The association between plasma MIF levels and MIF
haplotypes was explored. As shown in Figure 1B,
patients with the C5 haplotype had higher serum MIF
expression than those with the G7 haplotype (P =
0.0355). This was also observed in healthy controls (P =
0.044),
DNA methylation status of the CpG island in the MIF
promoter
The expression of MIF in PBMC was significantly
increased in AOSD patients compared with controls (P
= 0.017, Figure 2A). However, sequencing of PCR-
amplified bisulfate-treated DNA indicated that only
three methylated CpG sites were detected in three of
fifty sequences from AOSD patients, while methylation
was not detected in fifty sequences from ten healthy
donors (Figure 2B).
Discussion
AOSD is a systemic inflammatory disorder of unknown
etiology. The incidence of this disease is relatively low
and there are currently no reports of its prevalence in
China. It is well-known that environmental factors and
gene susceptibility play important roles in the
pathogenesis of autoimmune inflammatory diseases.
Genes involved in innate and adaptive immunity can
contribute to immune abnormalities. MIF, an upstream
regulator of cytokines involved in inflammatory diseases,
is an excellent example. We previously showed serum
MIF levels to be highly increased in AOSD patients
compared with those with infection, neoplasm, and rheu-
matic arthritis, and in controls [13]. However, the factors
leading to the abnormal production of MIF in AOSD
remain unresolved. Based on our previous description of
an association between MIF expression with severity and
disease activity in AOSD and prior reports of a correla-
tion between MIF functional promoter polymorphisms
with several inflammatory diseases, we were prompted to
study the role of MIF gene polymorphisms in disease sus-
ceptibility, clinical expression and plasma MIF concentra-
tions in AOSD.
In the present study, we genotyped the -173 SNP and
-794 CATT5-8 MIF promoter polymorphisms in AOSD
patients and controls. The allele frequencies in control
groups in our study were similar to another study in
which Chinese Han were studied [25]. An increased fre-
quency of haplotypes comprising -173*C/-794 CATT5
(C5) was observed in patients compared with controls,
which confers an increased risk of AOSD. This partly dif-
fers from the previous finding that the MIF alleles,
-173*C or -794 CATT7, are associated with the incidence
or severity of a number of inflammatory conditions,
including rheumatoid arthritis [15], juvenile inflamma-
tory arthritis [16], inflammatory bowel disease [26], celiac
disease [27] and asthma [28]. This association also was
evident in a Spanish population diagnosed with SLE [29].
Notably, in a recent study of SLE, a dual effect of the
-794 CATT polymorphism was noted with the low
expression CATT5 found to be associated with disease
susceptibility and the CATT7 allele with clinical severity
[17]. Numerous studies based on defined reporter assays
[15] or plasma MIF levels in different disease [17,30] sup-
port the designation of CATT7 as a high expression MIF
allele. By contrast, there are fewer functional data for the
-173*C allele, and its association with increased MIF
expression may reside in its strong linkage disequilibrium
with -794 CATT7, although to date, most studies have
been confined to Caucasian populations. Notably, there
are marked differences in the prevalence of -173*C in
the Chinese versus Caucasian or African populations.
In the present study, we found no significant difference
in the frequencies of -173*C between patients and con-
trols. However, Sreih and colleagues detected the fre-
quency of -173*C-containing genotype was lower in SLE
patients than in controls in African Americans but not in
Caucasian populations [17]. It remains possible that this
variant allele interacts functionally with the -794 CATT
locus.






OR (95% CI) P-value
C5 10(5.32) 4(1.00) 5.534 (1.712, 17.882) 0.001
C6 12(6.38) 28(7.04) 0.901 (0.448, 1.814) 0.770
C7 12(6.38) 21(5.28) 1.224 (0.589, 2.544) 0.588
G5 82(43.62) 138(34.67) 1.474 (1.034, 2.101) 0.032
G6 51(27.13) 153(38.44) 0.596 (0.408, 0.871) 0.007
G7 20(10.64) 42(10.55) 1.066 (0.612, 1.857) 0.822
G8 1(0.53) 12(3.02) 0.172 (0.022, 1.333) 0.057
AOSD, adult-onset Still’s disease.
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Subset analysis showed that plasma levels of MIF in
AOSD patients with the CC genotype were higher than
those with the GC or GG genotypes, although the differ-
ence was not significant. Our data also indicated that
patients with established AOSD who had a -794 CATT7
containing genotype have a higher prevalence of liver
damage. This conclusion is consistent with previous
reports that MIF gene polymorphisms affect clinical
manifestation and disease severity in certain inflamma-
tory disorders [15,17,26,31].
Beyond the influence of promoter polymorphisms on
the RNA transcription, DNA methylation is an addi-
tional, epigenetic mechanism that influences gene
expression without affecting the underlying DNA
sequence. We explored the association between the
methylation status of a CpG island in the MIF promoter
and MIF gene expression in PBMCs from AOSD
patients and healthy donors. Our data indicate that
DNA methylation is rare within the MIF promoter in
both controls and AOSD patients. While these data
Figure 1 Plasma levels of macrophage migration inhibitory factor. (A) Comparison of plasma levels of macrophage migration inhibitory
factor (MIF) between controls and patients and also in subsets of case group. (B) Comparison of plasma MIF expression in subgroups according
to different haplotypes in both patients and healthy controls. AOSD, adult-onset Still’s disease.
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suggest that DNA methylation may not be a significant
mechanism affecting MIF expression in the PBMCs of
AOSD patients, it remains possible that additional epi-
genetic mechanisms such as histone modification or
small regulatory RNAs do play a role [32].
In summary, we investigated for the first time the asso-
ciation between functional MIF polymorphisms and
AOSD. Our results suggest that MIF gene variants indeed
play a role in susceptibility of AOSD, clinical manifesta-
tions, and plasma MIF expression. Further studies are in
order to extend and confirm these initial findings in the
Chinese Han as well as other populations and to validate
the predictive value of MIF genotype or MIF plasma
levels in the clinical course and treatment response.
Conclusion
Functional promoter polymorphisms in the MIF gene
influence plasma MIF levels in AOSD and may contri-
bute to disease susceptibility or clinical presentation of
AOSD.
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